Decoding Zmiz1: a key transcription coactivator in development and disease

ZMIZ1, a zinc finger MIZ-type transcriptional co-activator in the PIAS family, is emerging as a central regulator at the interface of development and disease. Through interactions with key signaling effectors, including NOTCH1, SMAD3/4, p53, estrogen receptor, and androgen receptor, ZMIZ1 shapes transcriptional programs that govern embryogenesis, vascular and lymphatic development, and cerebral cortex development. Disruption of these programs is increasingly linked to human pathology: pathogenic ZMIZ1 variants cause a syndromic neurodevelopmental disorder with autism spectrum disorder and intellectual disability, and are associated with Hirschsprung disease, depression, and Lewy body disease. Beyond the nervous system, genetic and functional studies implicate ZMIZ1 in T-cell development and leukemia, multiple autoimmune diseases, type-2 diabetes, and a broad spectrum of cancers, including cutaneous squamous cell carcinoma, prostate, breast, colorectal cancer, osteosarcoma, and glioblastoma. Despite this expanding disease spectrum, the cell type-specific and context-dependent mechanisms by which ZMIZ1 integrates activation state from different signaling pathways, chromatin regulation, and transcription activation remain poorly understood. In this review, we synthesize current knowledge of ZMIZ1 and molecular regulatory networks across developmental, neurological, immune, metabolic, and oncologic contexts. We highlight convergent themes in ZMIZ1 biology, outstanding mechanistic questions, and emerging evidence supporting ZMIZ1 and its downstream pathways as potential diagnostic, prognostic, and therapeutic targets in human disease. By integrating genetic, molecular, and systems-level evidence across diverse organs and diseases, this review proposes a working model of ZMIZ1 as a partner-directed, dosage-sensitive transcriptional rheostat, identifies experiments required to test it, and appraises the current, largely preclinical, evidence for its clinical potential.